TD Asset Management
NVCR icon

TD Asset Management’s NovoCure NVCR Stock Holding History

TD Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,532
Closed -$317K – 1275
2025
Q3 		$317K Buy
24,532
+5,284
+27% +$70.6K ﹤0.01% 1201
2025
Q2 		$343K Sell
19,248
-28,964
-60% -$505K ﹤0.01% 1152
2025
Q1 		$859K Sell
48,212
-204,942
-81% -$4.65M ﹤0.01% 1093
2024
Q4 		$7.54M Sell
253,154
-97,600
-28% -$2.07M 0.01% 707
2024
Q3 		$5.48M Buy
350,754
+56,002
+19% +$1.02M ﹤0.01% 776
2024
Q2 		$5.05M Buy
294,752
+13,252
+5% +$233K ﹤0.01% 764
2024
Q1 		$4.4M Buy
281,500
+15,000
+6% +$221K ﹤0.01% 807
2023
Q4 		$3.98M Buy
266,500
+56,400
+27% +$755K ﹤0.01% 817
2023
Q3 		$3.39M Sell
210,100
-40,548
-16% -$1.17M ﹤0.01% 815
2023
Q2 		$10.4M Buy
250,648
+11,177
+5% +$694K 0.01% 591
2023
Q1 		$14.4M Buy
239,471
+130,291
+119% +$10.4M 0.02% 512
2022
Q4 		$8.01M Sell
109,180
-15,700
-13% -$1.18M 0.01% 643
2022
Q3 		$9.62M Buy
124,880
+1,000
+0.8% +$78K 0.01% 601
2022
Q2 		$8.61M Buy
123,880
+15,200
+14% +$1.15M 0.01% 644
2022
Q1 		$9M Buy
108,680
+46,816
+76% +$3.45M 0.01% 684
2021
Q4 		$4.64M Buy
61,864
+5,106
+9% +$513K ﹤0.01% 888
2021
Q3 		$6.59M Sell
56,758
-1,770
-3% -$268K 0.01% 759
2021
Q2 		$9.01M Buy
58,528
+20,248
+53% +$3.94M 0.01% 679
2021
Q1 		$5.06M Sell
38,280
-471
-1% -$74.5K 0.01% 815
2020
Q4 		$6.71M Buy
38,751
+9,791
+34% +$1.34M 0.01% 708
2020
Q3 		$3.22M Buy
28,960
+1,400
+5% +$112K ﹤0.01% 812
2020
Q2 		$1.63M Buy
27,560
+400
+1% +$26.3K ﹤0.01% 927
2020
Q1 		$1.83M Sell
27,160
-3,600
-12% -$285K ﹤0.01% 855
2019
Q4 		$2.59M Sell
30,760
-13,600
-31% -$1.1M ﹤0.01% 871
2019
Q3 		$3.32M Sell
44,360
-36,400
-45% -$2.91M 0.01% 784
2019
Q2 		$5.11M Buy
80,760
+20,360
+34% +$1.03M 0.01% 681
2019
Q1 		$2.91M Buy
60,400
+4,200
+7% +$202K ﹤0.01% 828
2018
Q4 		$1.88M Buy
+56,200
New +$2.06M ﹤0.01% 923

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

TD Asset Management's NVCR Position: Q4 2025 in Review

TD Asset Management sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 24,532 shares — an estimated $317K sold.

TD Asset Management first reported a position in NVCR in Q4 2018 and held it in 28 quarters. The position peaked at $14.4M in Q1 2023. 239 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

  • TD Asset Management reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
  • TD Asset Management sold 24,532 NovoCure shares in Q4 2025, an estimated $317K.
  • TD Asset Management first reported a position in NovoCure in Q4 2018 and held it in 28 quarters.
  • TD Asset Management's NovoCure position peaked at $14.4M in Q1 2023.
  • 239 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on TD Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.